Results 31 to 40 of about 48,421 (285)

Plasma Hepatocyte Growth Factor for Diagnosis and Prognosis in Light Chain and Transthyretin Cardiac Amyloidosis

JACC. CardioOncology, 2020
Objectives: This study determined the diagnostic and prognostic usefulness of hepatocyte growth factor (HGF) in light chain and transthyretin cardiac amyloidosis.
Kathleen W. Zhang, MD, Jennifer Miao, MD, Joshua D. Mitchell, MD, Jose Alvarez-Cardona, MD, Kelsey Tomasek, BS, Yan Ru Su, MD, Mary Gordon, RN, R. Frank Cornell, MD, Daniel J. Lenihan, MD   +8 more
doaj   +1 more source

Potential clinical relevance of cardiac magnetic resonance to diagnose cardiac light chain amyloidosis.

PLoS ONE, 2022
BackgroundWhile patients with cardiac transthyretin amyloidosis are easily diagnosed with bone scintigraphy, the detection of cardiac light chain (AL) amyloidosis is challenging.
Zsofia Dohy, Liliana Szabo, Zoltan Pozsonyi, Ibolya Csecs, Attila Toth, Ferenc Imre Suhai, Csilla Czimbalmos, Andrea Szucs, Anna Reka Kiss, David Becker, Bela Merkely, Hajnalka Vago   +11 more
doaj   +1 more source

Transthyretin levels in the vitreous correlate with change in visual acuity after vitrectomy [PDF]

, 2009
Background/aim: Little is known about biochemical markers related to change in visual acuity after vitrectomy. The potential use of transthyretin (TTR), a carrier of the retinol/retinol-binding protein, as a biochemical marker protein, was investigated ...
De Letter, Els, Delanghe, Joris, Delanghe, S, Derycke, Lara, Geers, I, Van Aken, Elisabeth, van Enschot, T, Veckeneer, M   +7 more
core   +3 more sources

Rapid decline in ejection fraction and persistent elevation of troponin associated with cardiac amyloidosis

SAGE Open Medical Case Reports, 2020
Cardiac amyloidosis is an increasingly recognized cause of heart failure. It remains underdiagnosed despite a significant morbidity and mortality rate. The mean survival in patients with cardiac amyloidosis is less than 1 year in untreated primary light ...
Temidayo Abe, Eric Y Chang, Gabrielle De Allie, Taiwo Ajose, Chukwuemeka Nwokike, Nicolas Bakinde   +5 more
doaj   +1 more source

Systemic amyloidosis in England: an epidemiological study. [PDF]

, 2013
Epidemiological studies of systemic amyloidosis are scarce and the burden of disease in England has not previously been estimated. In 1999, the National Health Service commissioned the National Amyloidosis Centre (NAC) to provide a national clinical ...
Banypersad, SM, Dungu, J, Gibbs, SD, Gillmore, JD, Hawkins, PN, Lachmann, HJ, Pinney, JH, Smith, CJ, Taube, JB, Venner, CP, Wechalekar, AD, Whelan, CJ   +11 more
core   +1 more source

Cardiac Amyloidosis Treatment

Methodist DeBakey Cardiovascular Journal, 2022
Cardiac amyloidosis (CA) is a restrictive cardiomyopathy with a traditionally poor prognosis. Until recently, CA treatment options were limited and consisted predominantly of managing symptoms and disease-related complications. However, the last decade has seen significant advances in disease-modifying therapies, increased awareness of CA, and improved
Lily K. Stern, Jignesh Patel
openaire   +3 more sources

Cardiac Transthyretin Amyloidosis: Hidden in Plain Sight

Case Reports in Medicine, 2021
Amyloidosis is an underappreciated medical condition with symptoms camouflaging as common medical comorbidities leading to its underdiagnosis due to its systemic involvement.
Constantine N. Logothetis, Joel Fernandez, Damian A. Laber   +2 more
doaj   +1 more source

Transthyretin cardiac amyloidosis.

Medicine and pharmacy reports, 2021
Transthyretin amyloid cardiomyopathy (ATTR-CM) may be an under recognized cause of heart failure (HF). TTR amyloidosis can be inherited, caused by variants in the TTR gene (ATTRv) or by deposition of wild-type TTR protein (ATTRwt), leading to high mortality if untreated.
Tomoaia, Raluca, Beyer, Ruxandra, Manole, Simona, Chirilă, Alina, Dădârlat-Pop, Alexandra, Minciună, Ioan Alexandru, Pop, Dana   +6 more
openaire   +2 more sources

Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis [PDF]

, 2017
Aims: Congo red staining of an endomyocardial biopsy is the diagnostic gold-standard in suspected cardiac amyloidosis (CA), but the procedure is associated with the risk, albeit small, of serious complications, and delay in diagnosis due to the ...
Botcher, N, Fontana, M, Gilbertson, JA, Gillmore, JD, Gonzalez-Lopez, E, Hawkins, PN, Lachmann, HJ, Mahmood, S, Petrie, A, Quarta, CC, Rezk, T, Rowczenio, D, Sachchithanantham, S, Wechalekar, AD, Whelan, CJ, Youngstein, T   +15 more
core   +1 more source

Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy

ESC Heart Failure, 2021
Aims As evidenced by scintigraphy imaging, the prevalence of transthyretin (TTR) cardiac amyloidosis in heart failure patients with preserved ejection fraction (HFpEF) and left ventricular hypertrophy (LVH) ranges between 13% and 19%.
Ana Devesa, Andrea Camblor Blasco, Ana María Pello Lázaro, Elham Askari, Gregoria Lapeña, Sandra Gómez Talavera, Mikel Taibo Urquía, Celia Rodríguez Olleros, José Tuñón, Borja Ibáñez, Álvaro Aceña   +10 more
doaj   +1 more source